a Exclusions were done sequentially. We included participants who were prescribed any of the following medications: (1) statin; (2) metformin; (3) sulfonylureas (including glipizide and gliclazide); (4) meglitinides (including repaglinide and nateglinide); (5) thiazolidinediones (including rosiglitazone and pioglitazone); (6) dipeptidyl peptidase-4 inhibitors (including sitagliptin, saxagliptin, linagliptin, and alogliptin); (7) glucagon-like peptide 1 agonists (including exenatide and liraglutide); and (8) angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors; were prescribed a 30-day supply of medication; had a 40% to 80% compliance for relevant medications in the 12 months prior to randomization; were not on the do-not-contact list prior to randomization; had a birthday from January 21 to April 21; and were not living with any other participant in our sample.
b Researchers at the University of Pennsylvania used R, version 3.1.1 (R Core Team) to randomly assign participants to conditions. Participants whose birthdays were between January 21 and March 31 were assigned to 1 of 5 conditions under a 1:1:1:1:1 allocation ratio. Participants who birthdays were between April 1 and April 21 were assigned to the control, new year unframed, or new year framed condition under a 1:1:1 allocation ratio. Participants were enrolled by Humana. All conditions were balanced on available demographic variables (age, sex, race/ethnicity, and income) and proportion of days covered prior to our randomized clinical trial (RCT), suggesting that our randomization was successful.
side of the research context. The formal trial protocol can be found in the Supplement.
For each participant, we used pharmacy claims data to calculate the proportion of days covered during our 90-day postmailing observation period, defined as the number of days he/ she had any pills in the medication category listed on his/her reminder divided by 90 days. Ordinary least squares regressions to estimate treatment effects in STATA, version 14 (StataCorp) had an 80% power to detect a difference of at least 2 percentage points between the control and each treatment condition with α = .05.
Results | Mean proportion of days covered among participants was 63.3% over 90 days postmailing. Compared with the control condition, proportion of days covered did not significantly differ in the birthday unframed (mean difference, 0.56%; 95% CI, −1.09% to 2.19%), birthday framed (mean difference, 0.55%; 95% CI, −1.08% to 2.20%), new year unframed (mean difference, 1.32%; 95% CI, −0.32% to 2.95%), or new year framed condition (mean difference, 0.38%; 95% CI, −1.26% to 2.03%). The difference in proportion of days covered was also insignificant comparing the birthday unframed and birthday framed conditions (mean difference, −0.02%; 95% CI, −1.66% to 1.63) or the new year unframed and new year framed conditions (mean difference, −0.93%; 95% CI, −2.57% to 0.71%). Figure 2 depicts these results.
Discussion | Contrary to our expectations, sending reminders following fresh-start dates was not associated with increased medication adherence, and fresh-start-based framing was not associated with increased reminder effectiveness. We encourage further study before concluding that the psychology of fresh starts does not apply to medication adherence. Because fresh-start dates motivate individuals wishing to initiate goal pursuit, 3, 4 our timing-and framing-based treatments may increase the effectiveness of reminders when reminders involve goal-setting activities. Additionally, there is often a delay between a target fresh-start date and the date when treatment-condition reminders were actually received; in the New Year conditions, reminders often arrived in late January. Reminders received immediately after the target date could be more effective. Further investigation into alternative ways to leverage fresh starts 5 and compel patients to attend to public health messaging would be valuable. This study has several limitations. The insurer sent some customers medication adherence reminders outside of the randomized clinical trial, and we were unable to include a condition without reminders. Also, many participants were involved in another randomized clinical trial comparing reminders that ended shortly before this randomized clinical trial. Furthermore, our participants had lower medication adherence levels than those in other adherence studies (eg, a multisite study published in 2015 6 ), possibly because of our selection criteria. 
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New Year Framed
Error bars represent standard error. For each participant, our ordinary least squares regression controls for his or her proportion of days covered during the 90 days prior to the mailing date, sex, race/ethnicity, the linear and squared terms of age, log-transformed income, and the type of medication that was listed on the reminder (ie, diabetes, cholesterol, or blood pressure). By design, any differences between the control and treatment conditions reflect a combination of the time of year and the potential treatment effect of receiving a fresh-start reminder.
Letters
Role of the Funder/Sponsor: The funding organization, in collaboration with the academic investigators, provided input on the design and conduct of the study; oversaw the collection and management of the data; and contributed to the preparation, review, and approval of the manuscript as well as the decision to submit the manuscript for publication. The funding organization had no role in the analysis or interpretation of the data. 
Society of Thoracic Surgeons Score Variance Results in Risk Reclassification of Patients Undergoing Transcatheter Aortic Valve Replacement
The Society of Thoracic Surgeons (STS) score is the cornerstone of risk assessment for patients with symptomatic severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) in the United States. The current STS score model was implemented in 2008, and the coefficients are reestimated every year using the last 3-year study sample in the STS database. Figure 2 ). Forty percent of patients would not change classification. Mortality at 30 days and at 1 year was 11.9% and 27.1%, respectively.
Discussion | Certainly, risk assessment is influenced by additional factors, such as frailty, pulmonary hypertension, or liver disease, that we did not account for in this study. Nonetheless, the STS score remains the starting point for risk determination for all patients undergoing TAVR in the United States. Our 
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Letters Study Protocol 
Social and Biological Sciences
Study Instruments
Discuss the particulars of the research instruments, questionnaires and other evaluation instruments in detail. Provide validation documentation and or procedures to be used to validate instruments. For well know and generally accepted test instruments the detail here can be brief. More detail may be required for a novel or new instrument. For ethnographic studies identify any study instruments to be used (i.e. for deception studies) and describe in detail where, when and how the study will be conducted and who or what are the subjects of study. Note: For more information on how to conduct ethical and valid ethnographic research, follow the link For oral histories or interviews provide the general framework for questioning and means of data collection. If interviews or groups settings are to be audio taped or video taped describe in detail the conditions under which it will take place. Include a copy of any novel or new test instruments with the IRB submission. A few weeks before the beginning of the experiment, we will require data from Humana for customers who satisfy our criteria (e.g., being prescribed with specific 30 day medications, having a 40-80% compliance rate with refills; see criteria in the attached proposal). We will randomly assign participants to one of several experimental conditions (see the attached proposal). Based on the experimental condition, subjects will receive a mailing determined by the experimental condition. After the experiment, we will request data from Humana again (see detailed variable list in the attached proposal).
Group Modifications
Describe necessary changes that will or have been made to the study instruments for different groups. Subjects will receive a mailing from Humana that encourages them to take their medication. We will have one of three types of mailings corresponding to our experimental conditions: control, fresh start date, or fresh start framing (detailed in the attached proposal).
Method for Assigning Subjects to Groups
Describe how subjects will be randomized to groups. Of subjects who meet our criteria, subjects whose birthday falls into our study period will be randomly assigned to one of three experimental conditions: control, fresh start date, or fresh start framing. Those subjects will receive a mailing around their birthday or a holiday.
Administration of Surveys and/or Process
Describe the approximate time and frequency for administering surveys and/or evaluations. For surveys, questionnaires and evaluations presented to groups and in settings such as high schools, focus group sessions or community treatment centers explain how the process will be administered and who will oversee the process. For instance, discuss the potential issues of having teachers and other school personnel administer instruments to minors who are students especially if the content is sensitive in nature. Describe the procedure for audio and videotaping individual interviews and/or focus groups and the storage of the tapes. For instance, if audio tape recording is to be used in a classroom setting, describe how this will be managed if individuals in the class are not participating in the study. Explain if the research involves the review of records (including public databases or registries) with identifiable private information. If so, describe the type of information gathered from the records and if identifiers will be collected and retained with the data after it is retrieved. Describe the kinds of identifiers to be obtained, (i.e. names, social security numbers) and how long the identifiers will be retained and justification for use. We will send a mailing to subjects.
Data Management
Describe how and who manages confidential data, including how and where it will be stored and analyzed. For instance, describe if paper or electronic report forms will be used, how corrections to the report form will be made, how data will be entered into any database, and the person(s) responsible for creating and maintaining the research database. Describe the use of pseudonyms, code numbers and how listing of such identifiers will be kept separate from the research data. The data will be maintained by the study investigators and the research assistants. The study will not track any personally identifiable information, as participants will be tracked only with their unique, anonymous participant ID. So our data will be de-identified. 
Human Source Material*
Department budget code
None
Protocol
Objectives
Overall objectives
We are proposing an experiment to help Humana investigate when to launch programs or send messages that are designed to improve customers' engagement. In this experiment, we will test (a) whether Humana can increase the effectiveness of its messages by sending them to customers around fresh starts moments and (b) whether highlighting a recent fresh start event in Humana's messages can further increase customer engagement.
Background
Our past research has shown that certain life events and calendar events (e.g., a job change, a birthday, a holiday, Monday) feel like a "fresh start" to people and have the potential to motivate them to begin pursuing their health goals (e.g., exercising, starting a diet, quitting smoking).
Study Design
Design
Of subjects who meet our criteria, subjects whose birthday falls into our study period will be randomly assigned to one of three experimental conditions: control, fresh start date, or fresh start framing. Those subjects will receive a mailing around their birthday or a holiday.
Study duration
We will have data about potential subjects collected two weeks before launching the program. The experiment will run for a few months. Subjects have no required participation time, as data will be gathered from their records. Data will be collected three months after the experiment ends, and may be collected as soon as the experiment ends for preliminary analysis. We propose to start the study as soon as possible.
Characteristics of the Study Population
Target population Subjects will meet the following four criteria: 1. Prescribed any of the following medications: a. Statin b. Metformin c. Sulfonylureas (including glipizide and gliclazide) d. Meglitinides (including repaglinide and nateglinide) e. Thiazolidinediones (including rosiglitazone and pioglitazone) f. DPP-4 inhibitors (including sitagliptin, saxagliptin, linagliptin, and alogliptin) g. Glucagon-like peptide 1 agonists (including exenatide and liraglutide) h. ACE/ARB/DRI 2. Prescribed a 30-day supply of medication 3. Refill history for relevant medications over at least the past 12 months. 4. Subject has 40%-80% compliance with refilling relevant medications over the last 12 months. 
Subjects enrolled by Penn Researchers 70000
Subjects enrolled by Collaborating Researchers
Subject recruitment
There is not a formal recruitment process because Humana will contact its customer as part of its routine business operation. Humana will contact its customers only once for this study and prefers to treat this as part of its normal customer contact. Specifically, Humana sends a mailing to eligible customers to encourage customers to take medications. This is something that Humana routinely does to engage their customers. Customers are not asked to respond to Humana. Researchers at Penn will NOT directly interact with participants.
Will the recruitment plan propose to use any Penn media services (communications, marketing, etc.) for outreach via social media avenues (examples include: Facebook, Twitter, blogging, texting, etc.) or does the study team plan to directly use social media to recruit for the research? No
The following documents are currently attached to this item:
There are no documents attached for this item.
Subject compensation* Will subjects be financially compensated for their participation? No
As explained in the attached study protocol, we proposed to Humana that we would like to have at least 12000 eligible participants for this RCT. When filing this IRB application, we and Humana did not know the exact number of participants that would be enrolled for this RCT, since it depended on how many eligible participants Humana had based on our selection criteria. The actual enrollment number might be higher than 12000. Since Upenn IRB requires that researchers file a modification whenever the number of subjects they actually enroll exceeds the number of target enrollment, we decided to enter "70000" (as opposed to 12000) in response to the question of "subjects enrolled by Penn researchers", so we can ensure that our actual enrollment would not exceed the response here.
If there is subject compensation, provide the schedule for compensation per study visit or session and total amount for entire participation, either as text or separate document
Study Procedures
Suicidal Ideation and Behavior Does this research qualify as a clinical investigation that will utilize a test article (ie-drug or biological) which may carry a potential for central nervous system (CNS) effect(s)? No
Procedures
Procedure is attached.
The following documents are currently attached to this item:
Procedures (freshstartproposaldraft_08_21_2014.pdf)
Deception
Does your project use deception? No
Analysis Plan
We will use regression models (e.g., logistic regressions, ordinary least squares regression models).
The following documents are currently attached to this item:
Are you conducting research outside of the United States? No
Subject Confidentiality
The data will be collected with anonymous participant IDs and will not include information that can be directly used to identify individuals. Research data will be kept confidential on password-protected computers and managed only by research investigators and study personnel. It is not feasible to obtain informed consent from subjects in this study. It would be logistically difficult to obtain informed consent from subjects before Humana sends them a mailing or giving them a call. The whole project only involves sending customers ONE mailing or giving them ONE call. Contacting customers in advance to obtain an informed consent may cause greater annoyance and inconvenience to customers than sending them a mailing/giving them a call to encourage them to take medications, which they can voluntarily ignore. Also, the only link between the subject and the study would be the consent document. Furthermore, for many customers, introducing the idea of research into their relationship with Humana would be the most negative part of the entire experience in the study. Surprising customers are not conducive to building the relationships that Humana is attempting to solidify with its customers. Bringing up research could also cause the surprised customers to refuse encouraged healthy behaviors (in this case, taking medications) that they would otherwise have accepted. This would interfere with the internal objective of Humana, since it is interested in helping customers make wise health decisions. 2. Humana will contact their customers via their normal contact channels (e.g., by a mailing). From Humana's perspective, contacting customers to increase their engagement is part of its normal business operation. Humana will not accept recommendations from researchers that fundamentally alter its relationships with customers. Humana is willing to let us advise them on the implementation of the study. However, if our involvement as a researcher were to cease or had not ever occurred, Humana would still be encouraging their customers to engage in healthy behaviors. Any efforts by Humana to determine more effective ways of encouraging healthy behaviors would not be considered research under the federal regulations about human subjects because they would not be expected to contribute to generalizable knowledge. We are primarily providing Humana with advice on the design of messages so that they can contribute to generalizable knowledge. 3. Participants are customers have voluntarily participated in the services provided by Humana outside of the scope of this research. Humana will contact customers as its normal business operation, and we as researchers will not interact with or recruit participants. Humana will contact its customers only once for this study, and participants are not asked to respond to Humana in any way. So it is unclear what an opt-out option should look like. Customers are always welcome to contact Humana whenever they have questions about any communications (including the mailings/phone calls related to this project) they have with Humana.
Risk / Benefit
Potential Study Risks There is a minimal risk of a confidentiality breach. Because all of the data will be carefully maintained with anonymous participant IDs, it is unlikely that confidentiality or privacy will be breached.
Potential Study Benefits
Some patients may achieve better medication adherence and, consequently, better health from participating in this study. We also plan to form generalizable knowledge for whether this fresh start effect can help people with achieving their goals.
Risk / Benefit Assessment
This study presents minimal risk to participants. All participants have the potential benefit of achieving better medication adherence and health outcomes. This experiment should benefit Humana in increasing the effectiveness of its messages, and benefit society in general by determining whether a "fresh start" framing can help increase goal adherence.
General Attachments
Additional forms (freshstartproposaldraft_08_21_2014.pdf) Additional forms (riisciticertification.pdf)
Additional forms (freshstart_datauseagreement_08202014-hengchen.pdf)
Cover Letter (irb_cover_letter_08282014.docx)
